Sarepta Therapeutics (SRPT) Current Assets (2010 - 2026)

Sarepta Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• On a quarterly basis, Current Assets fell 5.04% year-over-year to $2.3 billion in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 5.04% decrease from a year earlier, with the FY2025 full-year figure at $2.5 billion, down 17.42% from the prior year.
• Current Assets slipped to $2.3 billion in Q1 2026 per SRPT's latest filing, from $2.5 billion in the prior quarter.
• Across five years, Current Assets topped out at $3.1 billion in Q4 2024 and bottomed at $2.3 billion in Q1 2026.
• The 5-year median for Current Assets is $2.5 billion (2025), against an average of $2.6 billion.
• Across the five-year window, Current Assets increased 20.16% in 2022 and declined 17.42% in 2025, its largest moves.
• Year by year, Current Assets stood at $2.6 billion in 2022, then grew by 0.84% to $2.6 billion in 2023, then rose by 19.16% to $3.1 billion in 2024, then slipped by 17.42% to $2.5 billion in 2025, then dropped by 8.99% to $2.3 billion in 2026.
• Per Business Quant, the three latest SRPT Current Assets figures stand at $2.3 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.7 billion (Q3 2025).